Exhibit 99.2
Eli Lilly and Company
Operating Results (Unaudited) — PRO FORMA ADJUSTED
(Dollars in millions, except per share data)
Operating Results (Unaudited) — PRO FORMA ADJUSTED
(Dollars in millions, except per share data)
Three Months Ended | Year Ended | |||||||||||||||||||
March 31 | June 30 | Sept. 30 | Dec. 31 | December 31 | ||||||||||||||||
2006 | 2006 | 2006 | 2006 | 2006 | ||||||||||||||||
Net sales | $ | 3,882.0 | $ | 4,049.6 | $ | 4,054.7 | $ | 4,459.9 | $ | 16,446.2 | ||||||||||
Cost of sales | 850.5 | 906.6 | 906.2 | 1,066.7 | 3,730.0 | |||||||||||||||
Research and development | 773.9 | 807.4 | 788.8 | 890.0 | 3,260.1 | |||||||||||||||
Marketing and administrative | 1,242.9 | 1,340.9 | 1,302.3 | 1,422.1 | 5,308.2 | |||||||||||||||
Operating income | 1,014.7 | 994.7 | 1,057.4 | 1,081.1 | 4,147.9 | |||||||||||||||
Net interest expense | (38.8 | ) | (35.9 | ) | (34.2 | ) | (17.2 | ) | (126.1 | ) | ||||||||||
Joint venture income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |||||||||||||||
Net other income | 19.2 | 24.8 | 29.4 | 56.1 | 129.5 | |||||||||||||||
Other income (deductions) | (19.6 | ) | (11.1 | ) | (4.8 | ) | 38.9 | 3.4 | ||||||||||||
Income before income taxes | 995.1 | 983.6 | 1,052.6 | 1,120.0 | 4,151.3 | |||||||||||||||
Income taxes | 205.3 | 204.9 | 220.6 | 226.6 | 857.4 | |||||||||||||||
Net income | $ | 789.8 | $ | 778.7 | $ | 832.0 | $ | 893.4 | $ | 3,293.9 | ||||||||||
Earnings per share — diluted | $ | 0.73 | $ | 0.72 | $ | 0.77 | $ | 0.82 | $ | 3.03 | ||||||||||
Weighted-average shares outstanding (thousands) — diluted | 1,086,994 | 1,085,310 | 1,086,412 | 1,089,097 | 1,087,490 |
(a) | In accordance with generally accepted accounting principles (GAAP), the 2006 financial statements have been restated assuming the acquisition of ICOS was completed by Lilly effective January��1, 2006. | |
(b) | The fourth quarter and full year 2006 amounts are adjusted to eliminate the $494.9 million (pretax), or $.42 per share (after tax), charge to cover Zyprexa product liability settlements and claims costs, and the $450.3 million (pretax), or $0.31 per share (after tax) charge for asset impairments, restructuring and other special charges. |